Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The 
molecule is a recombinant protein analog of factor Xa that binds to Factor Xa 
inhibitors and antithrombin:LMWH complex but does not trigger prothrombotic 
activity. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) 
was able to dose-dependently reverse Factor Xa inhibition and restore thrombin 
generation for the duration of drug administration. Further trials are underway 
to examine its safety and efficacy in the population of patients experiencing 
FXa inhibitor-related bleeding.